Nemaura Medical

NMRD · OTC

$0.0001+$0.00 (+0.00%)TodayMarket closed · Oct 20, 9:30 AM ET

No price history for this range.

About NMRD

Nemaura Medical, Inc. operates as a holding company. The company is headquartered in Manhattan, New York and currently employs 36 full-time employees. The company went IPO on 2014-11-04. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes and may also be used to screen pre-diabetic patients and support obesity and weight-loss programs. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm. The Company’s applications of its technology include glucose monitoring, temperature monitoring, lactate monitoring, alcohol monitoring, and substance abuse monitoring. Its platform uses precision microsystems-based technology.

Employees: 36
Headquarters: Manhattan, New York
Listed: Nov 4, 2014
Sector: Health Care
Industry: Health Care Equipment & Supplies
Website: nemauramedical.com

Leadership

Nemaura Medical executives
Name	Title	Since	Age
Dewan Chowdhury	—	2009	50
Ruhksana Qayyum	—	—	58
Timothy Johnson	—	—	39
Thomas Moore	—	—	59

Similar companies

Companies in the same industry as Nemaura Medical

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.